Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Recipharm AB (publ)    RECI B   SE0005757267

RECIPHARM AB (PUBL)

(RECI B)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Recipharm publ : Invitation to the presentation of Recipharm's interim report January - June 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/22/2019 | 04:01am EDT

Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.

The company invites investors, analysts and media to a web conference (in English) on 25 July at 10:00 am CET, where CEO Thomas Eldered and CFO Tobias Hägglöv will present and comment on the report as well as answer questions.

The report will be available on Recipharm's website www.recipharm.com/investor-relations from 7:45 am CET the same day and the presentation from the webcast will be uploaded during the day on the 25th July.

To participate in the web conference, please use the below link:

https://webinars.on24.com/EMEA/RecipharmQ2_2019

Questions may be submitted by dialing below telephone numbers during the conference. If you don't wish to ask questions by telephone you only need to participate through the link above.

From Sweden: +46 8 566 426 51
From France: + 33 170 750 711
From Germany: +49 691 380 34 30
From India: +91 226 187 51 27
From Israel: +972 372 076 79
From Italy: +39 023 601 38 21
From Portugal: +351 210 609 105
From Spain: +34 935 472 900
From the UK: +44 333 300 08 04
From the USA: +1 631 913 14 22

Pin code for participants:
68033027#

For more information, please contact:
ir@recipharm.com, telephone: +46 8 602 52 00

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com

https://news.cision.com/recipharm-ab/r/invitation-to-the-presentation-of-recipharm-s-interim-report-january---june-2019,c2866313

https://mb.cision.com/Main/9273/2866313/1079827.pdf

(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RECIPHARM AB (PUBL)
07/25RECIPHARM AB : publishes its interim report January - June 2019
AQ
07/22RECIPHARM PUBL : Invitation to the presentation of Recipharm's interim report Ja..
AQ
05/14RECIPHARM PUBL : Bulletin from Annual General Meeting in Recipharm AB
AQ
05/13RECIPHARM PUBL : Bulletin from Annual General Meeting in Recipharm AB (publ)
AQ
05/07RECIPHARM PUBL : launches Inhalation SolutionsTM as its end-to-end offering for ..
AQ
05/03RECIPHARM AB : publishes its interim report January-March 2019
AQ
04/30RECIPHARM PUBL : Invitation to the presentation of Recipharm's interim report Ja..
PU
04/30RECIPHARM PUBL : Invitation to the presentation of Recipharm's interim report Ja..
AQ
04/29RECIPHARM AB (PUBL) : quaterly earnings release
04/17RECIPHARM PUBL : publishes Annual Report 2018
AQ
More news
Financials (SEK)
Sales 2019 7 393 M
EBIT 2019 580 M
Net income 2019 285 M
Debt 2019 3 653 M
Yield 2019 1,36%
P/E ratio 2019 27,3x
P/E ratio 2020 21,2x
EV / Sales2019 1,55x
EV / Sales2020 1,41x
Capitalization 7 778 M
Chart RECIPHARM AB (PUBL)
Duration : Period :
Recipharm AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECIPHARM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 150,40  SEK
Last Close Price 115,40  SEK
Spread / Highest target 47,3%
Spread / Average Target 30,3%
Spread / Lowest Target 1,39%
EPS Revisions
Managers
NameTitle
Thomas Bengt Eldered President, Chief Executive Officer, MD & Director
Lars Rickard Backsell Chairman
Tobias Hägglöv Chief Financial Officer
Carl-Johan Spak Executive Vice President-Global Technologies
Per Anders Gustav Carlberg Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RECIPHARM AB (PUBL)1.68%808
MERCK KGAA AG6.91%46 286
WUXI APPTEC CO LTD43.68%17 777
KYOWA KIRIN CO LTD-8.83%9 319
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD12.00%8 195
JAZZ PHARMACEUTICALS PLC7.98%7 579